GSK expanded its Chai Discovery AI drug-design partnership only after its own scientists validated the results, reflecting pharma's cautious AI embrace.
Cleveland Clinic and Dyania Health won a Gartner innovation award for AI that reportedly sped up clinical trial patient enrollment by about 40%.
Suki AI raised a $90 million Series E to expand its ambient scribe beyond note-taking into broader clinical agent tasks, entering a crowded field that includes Abridge, Ambience and Epic's own built-in tool.
Oracle Health and AstraZeneca are partnering to use AI for clinical trial patient recruitment, part of a broader industry push to speed up drug trials.
Roche's deal to acquire AI pathology startup PathAI, announced in May, is working toward a close as the pharmaceutical giant looks to speed up cancer diagnosis using artificial intelligence.
Tempus AI is pushing ahead with a roughly $1.5 billion all-stock acquisition of genomic testing company Personalis, a bet on expanding its precision oncology platform that sent both companies' shares lower when it was announced.
Pfizer has licensed Chai Discovery's AI protein design platform for its drug pipeline, as the startup diversifies beyond its existing Eli Lilly partnership following a $400 million funding round.
AI drug discovery licensing deals hit $47.1 billion in the first half of 2026, already surpassing all of 2025, even as no AI-discovered drug has yet won full FDA approval.
Takeda signed a $600 million AI drug discovery deal with Insilico Medicine, joining Eli Lilly and AstraZeneca in a wave of major pharma bets on AI-driven drug development in 2026.
Eli Lilly signed a deal worth up to $2.75 billion with Insilico Medicine to develop new drugs using AI, one of 2026's largest AI drug discovery partnerships.